FY2026 · ended Jun 30, 2026 · Revenue $5.65B, +9.9% YoY · Filed Aug 13, 2026
ResMed Inc. (RMD) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $5.7 billion and net income of $1.5 billion. Free cash flow was $1.6 billion. As of Sep 30, 2026 it held $1.0 billion in cash and investments and $770.6 million in total debt.
Revenue (TTM)
$5.73B
+9.0% vs year-ago TTM
Net income (TTM)
$1.59B
+10.8% vs year-ago TTM
Operating cash flow (TTM)
$1.77B
-6.0% vs year-ago TTM
Free cash flow (TTM)
$1.61B
-9.0% vs year-ago TTM
EPS (TTM)
$10.97
+12.3% vs year-ago TTM
Dividend per share (TTM)
$2.46
+12.3% vs year-ago TTM
Shares outstanding
144.25M
-1.5% vs prior year
Net cash
$240.19M
as of Sep 30, 2026
Operating margin
33.0%
FY 2027
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RMD (NYSE), RSMDF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 943819
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $5.7B | $5.1B | $4.7B | $4.2B | $3.6B |
| Operating income | $1.9B | $1.7B | $1.3B | $1.1B | $1.0B |
| Net income | $1.5B | $1.4B | $1.0B | $897.6M | $779.4M |
| Diluted EPS | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 |
| Operating cash flow | $1.8B | $1.8B | $1.4B | $693.3M | $351.1M |
| Free cash flow | $1.6B | $1.7B | $1.3B | $573.6M | $216.3M |
| Total assets | $9.0B | $8.2B | $6.9B | $6.8B | $5.1B |
| Total liabilities | $2.4B | $2.2B | $2.0B | $2.6B | $1.7B |
| Stockholders' equity | $6.6B | $6.0B | $4.9B | $4.1B | $3.4B |
| Cash and investments | $1.5B | $1.2B | $238.4M | $227.9M | $273.7M |
| Total debt | $1.1B | $861.7M | $883.8M | $1.6B | $927.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| ARS | Annual report to shareholders | Oct 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Auditor change, Officer or director change, Regulation FD disclosure
|
Aug 17, 2026 | Aug 13, 2026 |
| 10-K | Annual report | Aug 13, 2026 | Jun 30, 2026 |
All 1004 ResMed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.